InvestorsHub Logo
Followers 137
Posts 3718
Boards Moderated 0
Alias Born 05/10/2006

Re: None

Saturday, 09/19/2020 6:42:42 PM

Saturday, September 19, 2020 6:42:42 PM

Post# of 198921
1 MORE BIGGIE DD and TIES.

THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS


Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.

Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.

DD HER and Her Company!! Started at Novartis
Pharmaceuticals


https://stcbiologics.com/

STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.

She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.